Shionogi and Medicines Patent Pool Partner To Bring COVID-19 Anti-Viral To 117 Countries
Shionogi Follows Pfizer And Merck In Striking LMIC Anti-viral Agreement With MPP
A license agreement between Shionogi and the Medicines Patent Pool aims to widen access to Shionogi’s oral COVID-19 anti-viral ensitrelvir in low to middle-income countries. The investigational drug reduced Omicron-related symptoms in a recent Phase III trial.
